Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.

Pharmacogenomics - 1 Mar 2012

Ong Frank S, Deignan Joshua L, Kuo Jane Z, Bernstein Kenneth E, Rotter Jerome I, Grody Wayne W, Das Kingshuk

Abstract excerpt

In the past decade, significant strides have been made in the area of cardiovascular pharmacogenomic research, with the discovery of associations between certain genotypes and drug-response phenotypes. While the motivations for personalized and predictive medicine are promising for patient care and support a model of health system efficiency, the implementation of pharmacogenomics for cardiovascular therapeutics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Antihypertensive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Pharmacological

Share to Cardiovascular Diseases

Share to Clopidogrel

Share to Dose-Response Relationship, Drug

Share to Ticlopidine

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 22380001
DOI: 10.2217/pgs.12.2
PMCID: PMC3306231

Genes

ADRB1
ADD1
HMGCR
LDLR
VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.PMID 22380001Read ↗

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.Semantic proximity Read ↗

Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatmentSemantic proximity Read ↗

Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Semantic proximity Read ↗

Cardiovascular pharmacogenomics: current status and future directions.Semantic proximity Read ↗

Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab EmiratesSemantic proximity Read ↗

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).Semantic proximity Read ↗

Clinical implications of pharmacogenetic variation on the effects of statins.Semantic proximity Read ↗

Genetic determinants of response to cardiovascular drugs.Semantic proximity Read ↗

Is personalized medicine a dream or a reality?Semantic proximity Read ↗

Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.Semantic proximity Read ↗

Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.Semantic proximity Read ↗

When the same treatment has different response: The role of pharmacogenomics in statin therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.